General
Preferred name
AMINEPTINE
Synonyms
Amineptin ()
Dea no. 1219 ()
Amineptina ()
AMINEPTINE HYDROCHLORIDE ()
P&D ID
PD012473
CAS
57574-09-1
30272-08-3
Tags
available
drug
Drug indication
Major depressive disorder
Drug Status
approved
withdrawn
illicit
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Amineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
PHARMACODYNAMICS
Amineptine is an atypical tricyclic antidepressant.
INDICATION
For the treatment of depression.
METABOLISM
Hepatic.
HALF-LIFE
48 minutes for the parent drug and 2.5 hours for the metabolites.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
ReFrame library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
337.2
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
4.5
TPSA
49.33
Fraction CSP3
0.41
Chiral centers
0.0
Largest ring
7.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
Dopamine Receptor Agonists
Dopamine Receptor agonist
Target
SLC6A2, SLC6A4
ATC
N06AA19
Toxicity type
hepatic, dermatological
Source data
